Pentobarbital will decrease the level or effect of fentanyl transdermal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with CYP3A4 inducers could lead to a decrease Per fentanyl plasma concentrations, lack of efficacy or, possibly, development of a withdrawal syndrome Durante a patient who has developed https://socialistener.com/story5809055/considerazioni-da-sapere-su-pentobarbital-half-life